Heidelberg Pharma and Huadong Medicine strike licensing and investment agreement
The multimillion-dollar deal focuses on potential targeted cancer treatments and makes Huadong the strategic partner in Asia for Heidelberg Pharma’s product development
In a deal worth up to USD 930 million (EUR 825 million), Heidelberg Pharma has granted China's Huadong Medicine Co. exclusive license to develop and commercialise its two lead oncology candidates HDP-101 and HDP-103 in Asia, as well as exclusive opt-in rights for two more pipeline candidates.
The licensing deal covers Heidlberg Pharma's proprietary lead candidate HDP-101 is a B-cell maturation antigen (BCMA) antibody-targeted amanitin conjugate (ATAC) for multiple myeloma and its HDP-103, which is a PSMA ATAC for metastatic castration-resistant prostate cancer. Both are in clinical development.
ATACs, unlike standard therapeutics, are characterised by improved efficacy even on dormant tumour cells, which can contribute to tumour recurrence and resistance development.
The Germany-based biopharmaceutical company will receive an upfront payment of $20 million (€17.5 million) and milestone payments of up to $449 million (€400 million), and tiered royalties for each candidate.
The oncology specialist has also granted Huadong an exclusive option for the pre-IND research candidates HDP-102 (CD37-ATAC) for non-Hodgkin's lymphoma and HDP-104 (undisclosed target) in Asia (excluding India, Japan, Pakistan, Sri Lanka) with a total deal value of up to $461 million (€410 million).
In addition, the Chinese pharmaceutical company will also become the strategic partner in Asia for Heidelberg Pharma’s product development.
As part of the investment agreement Huadong intends to make an equity investment in Heidelberg Pharma totaling €105 million, representing 35% of total shares outstanding and therefore making it the second largest shareholder (dievini Hopp BioTech holding GmbH remains largest shareholder).
Related News
-
News CPHI Americas 2025 - From the Floor
Our From the Floor live blog is back in Philadelphia for this year’s CPHI, this time under the new name CPHI Americas to embrace and represent the whole of the pharmaceutical supply chain from north to south.
-
News Women in Pharma: Unlocking patient inclusion at CPHI Americas
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can towards making the healthcare industry and workplace more equitable and inclusive.&nbs... -
News Tracking Innovation with Thermo Fisher Scientific: CPHI Americas Track Sponsor interview
As we gear up for CPHI Americas from May 20-22, 2025 at the Philadelphia Convention Center, we sat down with Track Sponsor Thermo Fisher Scientific to discuss the future of bioproduction in pharma.
-
News Welcome back to the CPHI Exhibitor Spotlight!
We’re continuing our journey through the standout companies heading to CPHI Americas 2025, and next up is Adare - a global leader known for turning complex formulation challenges into innovative, patient-centric solutions.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News Executive order to elevate US pharma manufacturing signed by Trump
On Monday, May 5, US President Trump signed an executive order to reduce regulatory barriers for domestic US pharmaceutical manufacturing, including key ingredients and materials for manufacturing prescription drugs.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.